Novo Nordisk A/S (BKK:NOVOB80)

Market Cap	6.60T
Revenue (ttm)	1.61T
Net Income (ttm)	529.41B
Shares Out	n/a
EPS (ttm)	119.03
PE Ratio	12.47
Forward PE	12.08
Dividend	0.04 (2.68%)
Ex-Dividend Date	Aug 15, 2025

Volume	3,898,924
Average Volume	5,324,281
Open	1.520
Previous Close	1.530
Day's Range	1.480 - 1.520
52-Week Range	1.370 - 3.820
Beta	n/a
RSI	40.29
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 77,349
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: NOVOB80

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK